Efficacy and Safety of Once-Weekly Lonapegsomatropin in Adults With Growth Hormone Deficiency: foresiGHt Trial Results

Biller, Beverly MK; Gilis-Januszewska, Aleksandra; Doknic, Mirjana; Pico, Antonio; Fleseriu, Maria

Please use this identifier to cite or link to this item: https://hdl.handle.net/11000/39025

Efficacy and Safety of Once-Weekly Lonapegsomatropin in Adults With Growth Hormone Deficiency: foresiGHt Trial Results

View/Open:
FORESIGTH.pdf

844,43 kB
Adobe PDF
Share:

Title:
Efficacy and Safety of Once-Weekly Lonapegsomatropin in Adults With Growth Hormone Deficiency: foresiGHt Trial Results

Authors:
Biller, Beverly MK
Gilis-Januszewska, Aleksandra
Doknic, Mirjana
Pico, Antonio
Fleseriu, Maria

Editor:
Oxford University Press

Department:
Departamentos de la UMH::Medicina Clínica

Issue Date:
2025

URI:
https://hdl.handle.net/11000/39025

Abstract:
Adult growth hormone (GH) deficiency (GHD) is characterized by metabolic abnormalities caused by insufficient GH production. Lonapegsomatropin, a prodrug administered once weekly, was designed to provide sustained release of unmodified somatropin to reduce the burden of daily somatropin injections.

Keywords/Subjects:
Growth hormone
Growth hormone deficiency
Long-acting growth hormone
Adult growth hormone deficiency

Knowledge area:
CDU: Ciencias aplicadas: Medicina

Type of document:
info:eu-repo/semantics/article

Access rights:
info:eu-repo/semantics/openAccess
Attribution-NonCommercial-NoDerivatives 4.0 Internacional

DOI:
https://doi.org/10.1210/clinem/dgaf680

Published in:
The Journal of Clinical Endocrinology & Metabolism 2025

Appears in Collections:
Artículos Medicina Clínica

Show full item record View statistics

???jsp.display-item.text9???